India’s life-sciences sector faces scaling hurdles despite rapid innovation growth, report says

India’s life‑sciences sector has shown rapid growth, according to a new report by Boston Consulting Group and HealthKois. Patent filings have risen more than four‑fold since 2016, the pipeline of innovation assets grew by about 50 %, biotech start‑ups increased by 60 %, and private capital flowing into healthcare innovation surged.

Despite these gains, the report warns that the sector’s progress is uneven. Early‑stage research, clinical execution, consistent regulatory pathways and access to early‑stage funding remain significant gaps that limit the ability to scale innovation.

One of the authors highlighted that Indian‑origin science is now being licensed by global pharma majors and that indigenous CAR‑T therapies are being delivered to patients at a fraction of typical global costs.

The authors conclude that India’s life‑sciences industry stands at a turning point: it must address structural shortcomings if it wants to translate its growing innovation capacity into large‑scale impact.